moneyheap
ABSI · Analysis updated Nov 10, 2026, 6:00 PM ET
Why is Absci Corporation Common Stock (ABSI) stock moving?
Absci's only fresh news in the window is Jefferies initiating coverage with a Buy rating and a $14 target on Oct 29, which implies about 40% upside from the Nov 10 close of $9.97. The stock had already rallied before that news, with heavy volume of 5.8M shares on each of Oct 27 and Oct 28 as it rose from $9.45 to $11.88. It peaked at $12.10 on Oct 29, the initiation day, then gave back most of the gain, falling to $9.69 on Nov 2. Since then it has traded mostly between $9.00 and $10.80, with a 5.1M-share volume spike on Nov 5 on a drop to $9.39, and closed at $9.97 on Nov 10 on 4.1M shares. The analyst view is a clear positive, but the price has not held the initiation spike, and no SEC filings or earnings events fall in the 45-day window to add a fundamental catalyst.
News behind the analysis
- Jefferies Initiates Coverage On Absci with Buy Rating, Announces Price Target of $14Jefferies initiated coverage of Absci with a Buy rating and a $14 price target.
- Jefferies Initiates Coverage of Absci Corporation with Buy RatingAnalyst Andrew Tsai started coverage of Absci with a Buy rating and a $14 price target, roughly 40% above the Nov 10 close of $9.97.
About Absci Corporation Common Stock
Absci is a clinical-stage biotech company based in Vancouver, Washington, with AI labs in New York. It uses generative AI plus lab testing to design antibody drugs, and its lead candidate, ABS-201, is being tested for pattern hair loss and endometriosis.
How it makes money
Absci doesn't sell any approved drugs yet, so its revenue is small. It comes from partner programs with drug and tech companies, through upfront fees and milestone payments, and was only about $0.5 million in the first half of 2026. The company loses money (net loss about $63 million in the first half of 2026) and pays for its work mainly by selling new shares. One example is a roughly $100 million offering in June 2026 that included investment from Eli Lilly. Cash was about $201 million as of mid-2026, which the company says should last into 2028.
What usually moves ABSI
- ABS-201 clinical trial results (hair loss and endometriosis)
- Partnership deals and milestone payments
- Share sales that dilute existing holders, and how long its cash lasts
- Investor interest in AI drug discovery
- Overall biotech sector sentiment